Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD
1 other identifier
observational
92
0 countries
N/A
Brief Summary
- 1.Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.
- 2.To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2023
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2023
CompletedFirst Posted
Study publicly available on registry
October 5, 2023
CompletedStudy Start
First participant enrolled
November 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2026
ExpectedOctober 13, 2023
October 1, 2023
1.9 years
September 29, 2023
October 12, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.
Evaluation of the clinical utility of the measurement of the level of Cathepsin S and chromogranin A in type 2 diabetic nephropathy.
Baseline
Secondary Outcomes (1)
correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.
Baseline
Interventions
Diagnostic value of serum Cathepsin S and Chromogranin A
Eligibility Criteria
Patients with Type 2 diabetes mellitus from age 20 years to 80 years
You may qualify if:
- patients diagnosed as type 2 Diabetes mellitus
- Patients with T2DM with normoalbuminuria , microalbuminuria and macroalbuminuria.
You may not qualify if:
- Renal impairment of other Known origin,
- Type 1 D,
- Hepatic disease,
- Heart failure,
- Thyroid disorders,
- Autoimmune disorders,
- Inflammatory condition,
- Malignancy,
- Urinary tract infection,
- Pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Ren X, Wang W, Cao H, Shao F. Diagnostic value of serum cathepsin S in type 2 diabetic kidney disease. Front Endocrinol (Lausanne). 2023 May 25;14:1180338. doi: 10.3389/fendo.2023.1180338. eCollection 2023.
PMID: 37305031BACKGROUNDYu H, Wang H, Su X, Cao A, Yao X, Wang Y, Zhu B, Wang H, Fang J. Serum chromogranin A correlated with albuminuria in diabetic patients and is associated with early diabetic nephropathy. BMC Nephrol. 2022 Jan 21;23(1):41. doi: 10.1186/s12882-022-02667-0.
PMID: 35062888BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
September 29, 2023
First Posted
October 5, 2023
Study Start
November 1, 2023
Primary Completion
October 1, 2025
Study Completion (Estimated)
October 1, 2026
Last Updated
October 13, 2023
Record last verified: 2023-10